ASD141 / BRIM Biotech - LARVOL DELTA

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: Ascendo Biotechnology Co., Ltd. | Trial primary completion date: Aug 2026 ➔ Dec 2026

First-in-human • Trial primary completion date • Hepatocellular Cancer • Solid Tumor

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: Ascendo Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 (clinicaltrials.gov) - P1 | N=21 | Not yet recruiting | Sponsor: Ascendo Biotechnology Co., Ltd.

New P1 trial • Oncology • Solid Tumor

ASD141, an innate checkpoint inhibitor, modulates tumor associated myeloid cells through CD11b and enhances current immune checkpoint blockade in preclinical model (SITC 2021) - "Our results showed that combination of Xi2396 and anti-PD1 synergistically suppressed tumor growth. Conclusions Altogether, our results provide support for clinical efforts to evaluate ASD141 as an innate immune checkpoint drug, especially in combination with commercial immune checkpoint inhibitors."

Checkpoint inhibition • IO biomarker • Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD86 • ITGAM • MYD88 • PD-L1